Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylene Chloride SCHEMBL4557546 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL2391146 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL2456472 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL6704394 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL861591 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL4304807 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL3630221 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL7695098 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL5133360 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 | |
| Methylene Chloride SCHEMBL5091282 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104876940-B | A kind of synthetic method of fragrant folded formation hexatomic ring | 重庆大学 | 2017-04-05 | — | — | CN | disclosed |
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | ALDH1A1 2382/4885TDP1 3918/4885TRPA1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.